Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
about
Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimenMeta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapyChemotherapy-Induced Constipation and Diarrhea: Pathophysiology, Current and Emerging TreatmentsSimilar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patientsDiagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques.Breast cancer subtype specific classifiers of response to neoadjuvant chemotherapy do not outperform classifiers trained on all subtypesA proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer.HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination.Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.A Phase II trial of docetaxel and carboplatin administered every 2 weeks as preoperative therapy for stage II or III breast cancer: NCCTG study N0338.Neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin administered every 3 weeks for Japanese women with HER2-positive primary breast cancer: efficacy and safety.Non-pegylated liposomal Doxorubicin-cyclophosphamide in sequential regimens with taxanes as neoadjuvant chemotherapy in breast cancer patients.S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.Magnetic resonance imaging features of breast cancer according to intrinsic subtypes: correlations with neoadjuvant chemotherapy effects.Best management of locally advanced inoperable breast cancer.Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients.Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in womA Predictive Mathematical Modeling Approach for the Study of Doxorubicin Treatment in Triple Negative Breast CancerSorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA.Adherence to Treatment Guidelines in Breast Cancer Care - a Retrospective Analysis of the 'Organgruppe Mamma der Arbeitsgemeinschaft Gynaekologische Onkologie'New Therapeutic Options for Breast Cancer during Pregnancy.Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer.Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer.Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer.Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy.Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial.Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Comparison of Doxorubicin plus docetaxel neoadjuvant chemotherapy with Doxorubicin plus vinorelbine in primary breast cancerEfficacy of TCH/TEC neoadjuvant chemotherapy for the treatment of HER-2-overexpressing breast cancer.In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional studyHER2-directed therapy: current treatment options for HER2-positive breast cancer.Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer.Effect of targeted agents on the endocrine response of breast cancer in the neoadjuvant setting: a systematic review.Neoadjuvant therapy for locally advanced breast cancer: Focus on chemotherapy and biological targeted treatments' armamentarium.Role of plasma osteopontin as a biomarker in locally advanced breast cancerComparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
P2860
Q21092375-C65F4913-64BE-4684-ADBC-FD03026A48FAQ27024544-B8C6AB7D-A177-4372-B80F-8C9EC253763AQ28079705-D6364354-C231-4B84-9FCF-DB09EFFB4C9BQ28271961-3A540EB6-EC07-44A5-ACF8-7F8C3F4C1F6FQ30315973-4195F3C1-B37A-4724-97D5-4DC98DEA7DFEQ31151786-24307BF0-BA87-4818-8D94-CE92A1D8AD50Q33267359-B51D4A31-212E-4B24-8FAC-9DABB094F3D4Q33275622-8C5AA1DB-AFAA-451A-9A47-DFB8CE0F83F6Q33394310-4E226401-17E6-49F6-BE76-2993ED2C91BCQ33402700-6C642C13-C502-4118-8C26-DE2C33D09ECAQ33442144-F41B794B-3B50-47E6-84C6-3D6F512240F9Q33634964-F498A62E-917D-469D-B05E-8D7FC7832AA8Q33643492-ACC62333-F93D-4D3F-B175-8CAB3D1F8324Q33683126-FAD469DC-5ACD-44F7-8FCF-8C62232E4CDDQ33690733-C71FEEF9-657D-4512-911B-0EDE5721F9BBQ33699040-A34B8395-BD90-40E2-8FD6-9D92B4F6E77BQ33746929-DC0D8321-7564-4BD8-8A55-08C53D0CDF4EQ33904763-FC6B983E-15B4-4506-8BBB-2EA48F882D27Q33916210-1B52BA78-E8C1-4B41-86FE-1817AAEC69A5Q34042709-D4C253F8-07CE-486F-961D-1B94633551B0Q34096177-7C0B3D60-3D06-4535-9056-28C97C34A240Q34096331-31E81DEA-9A09-454A-86D3-8F34FD4D76E2Q34232366-B6AA6F6C-AADF-42EB-9344-674843AD57A7Q34315684-353F4F3D-FB0F-4E07-BB37-E34B2A0632C9Q34344198-1FD195D1-BE92-451B-BD02-7F818A412A04Q34616067-33538FEF-5B64-4AB8-944C-C55C7F641531Q34816825-F5EBD7F6-6BD7-4A20-B7F7-E5702AE32A06Q35060987-A461CE8D-6953-4998-B82A-2293990D8A55Q35130819-4EBB6018-D1C9-4217-BF44-1CD12F1F7F31Q35142230-153B4AD2-A045-4379-8C99-C1CEFDB9D4ECQ35167644-87EADB40-C913-4815-A1B9-FA8754CC4C0BQ35345516-622E6709-09F8-4F6E-80C2-8C2E76658E9BQ35539538-E67059B0-3296-405E-8473-264D008056DCQ35551522-8EA7DC8E-4852-49DE-A60C-0AAB1C31E455Q35576250-3490D63E-90E2-4548-BB63-001EFFB7394CQ35605856-A9777D2B-D079-4021-9592-1CCF1BEEEB88Q35631641-8FB3A10E-1423-4B35-BB46-EF8E1CFB5079Q35667692-FEEFD6BE-FE59-4997-8AC9-A3AA35D819DDQ35682597-4B327D78-BBC7-4F54-B753-F2E0F95F1F4CQ35783711-60A5597D-2DEB-4E3F-BFBE-71345E8C6C31
P2860
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Recommendations from an intern ...... able breast cancer: an update.
@en
Recommendations from an international expert panel on the use of neoadjuvant
@nl
type
label
Recommendations from an intern ...... able breast cancer: an update.
@en
Recommendations from an international expert panel on the use of neoadjuvant
@nl
prefLabel
Recommendations from an intern ...... able breast cancer: an update.
@en
Recommendations from an international expert panel on the use of neoadjuvant
@nl
P2093
P50
P356
P1476
Recommendations from an intern ...... able breast cancer: an update.
@en
P2093
Andreas Makris
Annette Lebeau
Aron Goldhirsch
Gabriel N Hortobagyi
Gunter von Minckwitz
Jens-Uwe Blohmer
Manfred Kaufmann
Pinuccia Valagussa
Raimund Jackesz
Rainer Souchon
P304
P356
10.1200/JCO.2005.02.6187
P407
P577
2006-04-01T00:00:00Z